The two compounding lanes
Compounding is what pharmacists do when they make a custom version of a drug that isn't commercially available off the shelf. There are two flavors under federal law.
503A is a state-licensed pharmacy filling a specific prescription for one named patient. Think of the local compounding pharmacy your dermatologist sends you to for a custom topical. They don't make drugs in bulk. Each script is one patient.
503B is an outsourcing facility. They do make drugs in bulk, with or without specific prescriptions in hand, and follow stricter manufacturing standards. They were a large part of how compounded semaglutide reached so many telehealth patients during the shortage years.
The April 30 announcement does two different things to these two lanes.
What FDA proposed for 503B
The proposal removes semaglutide, tirzepatide, and liraglutide from the 503B bulks list, the menu of drug substances outsourcing facilities are allowed to compound from active pharmaceutical ingredient in bulk. If these three are removed, 503Bs cannot compound them in bulk, full stop, unless they go back on the FDA shortage list (and right now they are not).
This is a proposal, not a final rule. The FDA opened a public docket for comment, which closes June 29, 2026. After that, the agency reviews comments and makes a final determination later in the year.
What FDA clarified for 503A (the bigger deal)
This is the part that matters more for most patients and providers, because 503A is where the “compounded GLP-1 from a telehealth doctor” supply largely lives now.
The FDA reiterated a longstanding rule that 503A pharmacies cannot compound a drug that is “essentially a copy”of a commercially available FDA-approved drug, “regularly or in inordinate amounts.” A compounded product is essentially a copy if it has the same active ingredient in the same or similar strength as the brand drug, administered the same way.
Three teeth in this:
- The exemption is patient-specific. A 503A pharmacy can compound an essentially-a-copy product when the prescribing practitioner determines and documents that the compounded version produces a clinically significant difference for that one patient. The FDA explicitly said this determination cannot be a general policy or boilerplate language across patients. It has to be made for the individual, written by the prescriber.
- Semaglutide-plus-B12 was specifically named. Generic justifications like “weight management with vitamin B12 supplementation” do not clear the bar, because the patient could just take the FDA-approved semaglutide and the B12 separately. The FDA was explicit about this.
- There is a low-volume safe harbor. The FDA does not currently intend to take action against a 503A pharmacy that fills four or fewer prescriptions per calendar month of an essentially-a-copy product. That carves out genuine occasional compounding. It does not protect any operation prescribing or filling at telehealth-clinic volumes.
What a doctor now has to put on the prescription
If you want a 503A pharmacy to legally compound semaglutide or tirzepatide for you under this framework, the prescription has to do two things at once.
It has to be for you by name, not a standing protocol.
And it has to include a patient-specific clinical reason the FDA-approved version will not work for you, written by the prescriber.
Acceptable
- "No Dye X, patient allergy" (when the FDA-approved product contains the dye)
- "Liquid form, patient cannot swallow tablet" (when only a tablet is commercial)
- "6 mg, patient needs dose not commercially available" (a custom titration step the manufacturer does not sell)
- A documented intolerance to a specific excipient in Wegovy, Ozempic, or Zepbound
Not acceptable
- "Cost" or "patient cannot afford the brand"
- "Patient prefers compounded"
- "Weight management with vitamin B12 supplementation" or any wellness combo whose only purpose is to dodge the rule
- Generic templates pasted across many patients
The pharmacist filling the script is supposed to verify the reason is documented. If it is missing or unclear, the pharmacist is supposed to call the prescriber and note the date of the conversation on the script.
What this means for patients
If you are currently on compounded semaglutide or tirzepatide, here is the practical breakdown.
- Most prescriptions filled by a major 503B outsourcing facility are on borrowed time. Those facilities are losing their pathway. Plan ahead with your prescriber.
- If your script is filled by a 503A pharmacy, ask whoever wrote it to walk you through the patient-specific clinical reason on the prescription. If the answer is “we add B12 to make it different” or “you're paying less than brand,” that script is not protected under the new framework.
- Brand-name access (Wegovy, Zepbound, Ozempic, Mounjaro) remains the cleanest path and is no longer in shortage.
- A real 503A relationship with a prescriber who knows your case and documents your specific clinical reason can still legally compound, including custom titration doses the manufacturer does not sell.
What this means for providers
Quietly, this is a clarifying moment for serious peptide medicine.
Providers who route through 503A pharmacies and document patient-specific clinical reasons on every script keep prescribing. Telehealth pill-mill operations that lean on 503B bulk supply, generic intake forms, and B12 add-ons are exposed.
If you are a clinic doing this the careful way, your work just became more visible, not less.
Sources
- FDA Press Release: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (April 30, 2026)
- FDA: Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
- Foley & Lardner: FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products
- National Law Review: FDA Offers Additional Clarification on Compounded GLP-1 Policy
This article is editorial information, not medical or legal advice. Talk to a licensed prescriber about your treatment and a healthcare attorney about your practice.